P3 Health Partners Inc. reported financial results for the second quarter ended June 30, 2026, announcing total revenue of $386 million and net income of $15.7 million, a significant improvement from the prior year's net loss of $43.7 million. Adjusted EBITDA reached $54.4 million compared to a $17.1 million loss in the previous period. The company raised its full-year 2026 adjusted EBITDA guidance range to between $80 million and $110 million, up from prior estimates. At-risk membership decreased by 10% year-over-year to approximately 105,000 members due to intentional network rationalization. P3 Health Partners Inc. operates in the population health management industry, providing value-based care coordination and administrative services for primary care providers.

P3 Health Partners Inc. subsidiary P3 Health Group, LLC entered into a Second Amendment to Repurchase Promissory Note with IHC Health Services, Inc. The amendment extends the maturity date of the existing Repurchase Promissory Note to September 30, 2028, and changes the interest rate to 14% per annum PIK interest starting June 30, 2026. P3 Health Partners Inc. operates in the healthcare services industry.

P3 Health Partners Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, where stockholders' votes resulted in the election of Class II directors Amir Bacchus, M.D., Mark Thierer, and Lawrence B. Leisure, and the ratification of BDO USA, P.C. as the company's independent registered public accounting firm. Stockholders also approved on an advisory basis executive officer compensation and approved the issuance of up to 3,341,130 shares of Class A common stock upon the exercise of outstanding Class A common stock warrants held by VBC Growth SPV 5, LLC. P3 Health Partners Inc. is a healthcare services company providing value-based care solutions.